Lambert Assoumou

3.3k total citations · 1 hit paper
78 papers, 1.4k citations indexed

About

Lambert Assoumou is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Lambert Assoumou has authored 78 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Infectious Diseases, 49 papers in Virology and 22 papers in Emergency Medicine. Recurrent topics in Lambert Assoumou's work include HIV Research and Treatment (48 papers), HIV/AIDS drug development and treatment (44 papers) and HIV/AIDS Research and Interventions (39 papers). Lambert Assoumou is often cited by papers focused on HIV Research and Treatment (48 papers), HIV/AIDS drug development and treatment (44 papers) and HIV/AIDS Research and Interventions (39 papers). Lambert Assoumou collaborates with scholars based in France, United States and Spain. Lambert Assoumou's co-authors include Dominique Costagliola, Christine Katlama, Robert L. Murphy, Jade Ghosn, Claudine Duvivier, Brigitte Autran, S. Kolta, Sylvie Rozenberg, Vincent Cálvez and Christine Rouzioux and has published in prestigious journals such as Annals of Internal Medicine, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Lambert Assoumou

72 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design

2024 69 citations Jean‐Michel Molina, Béatrice Berçot et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lambert Assoumou France	21	858	842	466	255	240	78	1.4k
Jean‐Marie Ragnaud France	20	692 0.8×	577 0.7×	404 0.9×	91 0.4×	273 1.1×	40	1.3k
Moti Ramgopal United States	21	1.1k 1.3×	901 1.1×	322 0.7×	250 1.0×	418 1.7×	83	1.5k
Jordi Navarro Spain	18	544 0.6×	562 0.7×	187 0.4×	183 0.7×	394 1.6×	77	1.1k
Nicoletta Ladisa Italy	23	732 0.9×	543 0.6×	298 0.6×	70 0.3×	356 1.5×	69	1.2k
Carmela Pinnetti Italy	17	596 0.7×	300 0.4×	173 0.4×	107 0.4×	340 1.4×	91	921
Antonia L. Moore United Kingdom	11	537 0.6×	362 0.4×	244 0.5×	27 0.1×	166 0.7×	17	742
Celia Miralles Spain	19	593 0.7×	394 0.5×	180 0.4×	41 0.2×	368 1.5×	53	1.2k
David Rey France	21	558 0.7×	305 0.4×	136 0.3×	92 0.4×	741 3.1×	67	1.2k
David Baker Australia	15	467 0.5×	346 0.4×	441 0.9×	15 0.1×	251 1.0×	30	918
Marialuisa Partisani France	15	598 0.7×	297 0.4×	391 0.8×	80 0.3×	351 1.5×	38	1.1k

Countries citing papers authored by Lambert Assoumou

Since Specialization

Citations

This map shows the geographic impact of Lambert Assoumou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lambert Assoumou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lambert Assoumou more than expected).

Fields of papers citing papers by Lambert Assoumou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lambert Assoumou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lambert Assoumou. The network helps show where Lambert Assoumou may publish in the future.

Co-authorship network of co-authors of Lambert Assoumou

This figure shows the co-authorship network connecting the top 25 collaborators of Lambert Assoumou. A scholar is included among the top collaborators of Lambert Assoumou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lambert Assoumou. Lambert Assoumou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hejblum, Gilles, Karine Amat, Sidonie Lambert-Niclot, et al.. (2025). Cost-effectiveness of a 4 days-a-week triple therapy in persons with HIV: an ancillary study of the QUATUOR trial. AIDS. 39(10). 1452–1461. 1 indexed citations

Berçot, Béatrice, Lambert Assoumou, François Caméléna, et al.. (2025). Antimicrobial-Resistant Neisseria gonorrhoeae Infections in Men Using Doxycycline Postexposure Prophylaxis: A Substudy of the ANRS 174 DOXYVAC Trial. Clinical Infectious Diseases.

Palich, Romain, Jade Ghosn, Karine Lacombe, et al.. (2025). Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study. Journal of Antimicrobial Chemotherapy. 81(1).

Lê, Minh, Clotilde Allavena, Véronique Joly, et al.. (2025). Switch to bictegravir/emtricitabine/tenofovir alafenamide in people living with HIV aged 65 years or older: BICOLDER study – IMEA 057. Journal of Infection and Public Health. 18(11). 102946–102946.

Ghosn, Jade, Lambert Assoumou, Emma Rubenstein, et al.. (2024). Impact of vaccination with third generation modified vaccinia Ankara and sexual behaviour on mpox incidence in men who have sex with men: analysis among participants of the ANRS-174 DOXYVAC trial. The Lancet Regional Health - Europe. 45. 101020–101020. 2 indexed citations

Abé, Emuri, Lambert Assoumou, Karine Amat, et al.. (2024). Plasma concentrations of antiretroviral drugs in a successful 4-days-a-week maintenance treatment strategy in HIV-1 patients (ANRS 170-Quatuor trial). Journal of Antimicrobial Chemotherapy. 79(6). 1380–1384.

Protière, Christel, Luis Sagaon‐Teyssier, Gabriel Girard, et al.. (2023). Perception of PrEP‐related stigma in PrEP users: Results from the ANRS‐PREVENIR cohort. HIV Medicine. 24(8). 938–945. 3 indexed citations

Ghosn, Jade, Lambert Assoumou, Caroline Lascoux‐Combe, et al.. (2021). HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection. The Journal of Infectious Diseases. 225(1). 116–120. 4 indexed citations

Molina, Jean‐Michel, Jade Ghosn, Constance Delaugerre, et al.. (2021). Incidence of HIV infection with daily or on-demand oral prep with TDF/FTC in france. 29(1). 43–44. 8 indexed citations

10.

Godin, Ophélia, Antoine Moulignier, François-Xavier Lescure, et al.. (2019). Brief Report: Impact of ART Classes on the Increasing Risk of Cerebral Small-Vessel Disease in Middle-Aged, Well-Controlled, cART-Treated, HIV-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes. 81(5). 547–551. 8 indexed citations

11.

Seang, Sophie, Thuy Nguyen, Minh Lê, et al.. (2017). Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia. Journal of Antimicrobial Chemotherapy. 73(2). 490–493. 5 indexed citations

12.

Gatell, José M., Lambert Assoumou, Graeme Moyle, et al.. (2017). Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS. 31(18). 2503–2514. 54 indexed citations

13.

Pourcher, Valérie, Aude Desnoyer, Lambert Assoumou, et al.. (2016). Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial. AIDS Research and Human Retroviruses. 33(1). 1–10. 24 indexed citations

14.

Funck-Brentano, Isabelle, Lambert Assoumou, Florence Veber, et al.. (2016). Resilience and Life Expectations of Perinatally HIV-1 Infected Adolescents in France. The Open AIDS Journal. 10(1). 209–224. 7 indexed citations

15.

Assoumou, Lambert, Laurence Weiss, Christophe Piketty, et al.. (2015). A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control. AIDS. 29(15). 2003–2007. 61 indexed citations

16.

Guihot, Amélie, Chiara Dentone, Lambert Assoumou, et al.. (2015). Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia. AIDS. 30(2). 327–330. 24 indexed citations

17.

Katlama, Christine, Sidonie Lambert-Niclot, Lambert Assoumou, et al.. (2015). Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA. AIDS. 30(2). 221–230. 54 indexed citations

18.

Piketty, Christophe, Laurence Weiss, Lambert Assoumou, et al.. (2010). A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. Journal of Medical Virology. 82(11). 1819–1828. 35 indexed citations

19.

Aslangul, E., Lambert Assoumou, Randa Bittar, et al.. (2009). Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS. 24(1). 77–83. 68 indexed citations

20.

Costagliola, Dominique, Diane Descamps, Lambert Assoumou, et al.. (2007). Prevalence of HIV-1 Drug Resistance in Treated Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 46(1). 12–18. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact